¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"common pathway of coagulation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ubiquitin-protease pathway
    À¯ºñÄûƾ´Ü¹éºÐÇØÈ¿¼ÒÅë·Î
  • visual pathway
    ½Ã°¢°æ·Î
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀå¾Ö
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • coagulation necrosis
    ÀÀ°í±«»ç
  • coagulation time
    ÀÀ°í½Ã°£
  • diffuse intravascular coagulation
    ±¤¹üÀ§Ç÷°ü³»ÀÀ°í
  • disseminated intravascular coagulation
    ÆÄÁ¾Ç÷°ü³»ÀÀ°í
  • electric coagulation
    Àü±âÀÀ°í(¼ú)
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • coagulation time
    ÀÀ°í½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀå¾Ö
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation necrosis
    ÀÀ°í±«»ç
  • coagulation time
    ÀÀ°í½Ã°£
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • diffuse intravascular coagulation
    ¹Ì¸¸Ç÷°ü³»ÀÀ°í
  • disseminated intravascular coagulation
    ÆÄÁ¾Ç÷°ü³»ÀÀ°í
  • electric coagulation
    Àü±âÀÀ°í¼ú
  • endolaser coagulation
    ´«¼Ó·¹ÀÌÀúÀÀ°í(¼ú), ¾È³»·¹ÀÌÀúÀÀ°í(¼ú)
  • intravascular coagulation
    Ç÷°ü³»ÀÀ°í
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glycolytic pathway
    ÇØ´ç°æ·Î
  • phosphogluconate oxidative pathway
    ±Û·çÄÜ»ê»êÈ­°æ·Î, ÀÎ´ç¿ø»êÈ­°æ·Î(ìÝÓØ ê«ß«ûùÌèÖØ).
  • pyruvate pathway
    ÇÇ·çºê»ê¿°´ë»ç°æ·Î(¡­ß«ç¤ÓÛÞóÌèÖØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • coagulation disorder
    ÀÀ°íÀÌ»ó
  • coagulation factor
    ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • coagulation factor
    ÀÀ°íÀÎÀÚ(¡­ì×í­).
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor deficiency
    ÀÀ°íÀÎÀÚ°áÇÌ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ ¾ïÁ¦Á¦<¾ïÁ¦ ¹°Áú
  • coagulation factors
    ÀÀ°íÀÎÀÚ(¡­ì×í­)
  • coagulation necrosis
    ÀÀ°í±«»ç(¡­ÎÕÞÝ)
  • coagulation test
    ÀÀ°í½ÃÇè(ëêͳãËúÐ).
  • coagulation time
    ÀÀ°í½Ã°£(¡­ãÁÊà) ¡ìÇ÷¾×ÀÇ¡í.
  • coagulation,disseminated intravascular
    ÆÄÁ¾¼º Ç÷°ü³» ÀÀ°í(÷ëðúàõúìηҮ¡­)
  • coagulation,fibrinolytic system
    ¼¶À¯¼Ò ¿ëÇØ°è(àéë«áÈéÁú°Í§)
  • diffuse intravascular coagulation
    ¹ü¹ß¼º Ç÷°ü³»ÀÀ°í.
  • disseminated intravascular coagulation
    ÆÄÁ¾¼º Ç÷°ü³»ÀÀ°í(÷ëðúàõúìηҮëêͳ)
  • disseminated intravascular coagulation
    ÆÄÁ¾¼ºÇ÷°ü³»ÀÀ°íÁõ(÷ëðúàõúìηҮëêͳñø)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Common iliac artery
    ¿Â¾ûµ¢µ¿¸Æ
    [¿¾ ¿ë¾î] ÃÑÀå°ñµ¿¸Æ
  • Common iliac lymph nodes
    ¿Â¾ûµ¢¸²ÇÁÀý
    [¿¾ ¿ë¾î] ÃÑÀå°ñÀÓÆÄÀý
  • Common iliac vein
    ¿Â¾ûµ¢Á¤¸Æ
    [¿¾ ¿ë¾î] ÃÑÀå°ñµ¿¸Æ
  • Common iliac vein
    ¿Â¾ûµ¢Á¤¸Æ
    [¿¾ ¿ë¾î] ÃÑÀå°ñÁ¤¸Æ
  • Common peroneal nerve
    ¿ÂÁ¾¾Æ¸®½Å°æ
    [¿¾ ¿ë¾î] ÃѺñ°ñ½Å°æ
  • Common pulmonary vein
    ¿ÂÇãÆÄÁ¤¸Æ
    [¿¾ ¿ë¾î] ÃÑÆóÁ¤¸Æ
  • Common peroneal sheath
    Á¾¾Æ¸®±Ù¿ÂÈûÁÙÁý
    [¿¾ ¿ë¾î] ºñ°ñ±ÙÃѰÇÃÊ
  • Common bile duct
    ¿Â¾µ°³°ü
    [¿¾ ¿ë¾î] ÃÑ´ã°ü
  • Sphincter muscle of common bile duct
    ¿Â¾µ°³°üÁ¶ÀÓ±Ù
    [¿¾ ¿ë¾î] ÃÑ´ã°ü°ý¾à±Ù
  • Sphincter of common bile duct
    ¿Â¾µ°³°üÁ¶ÀÓ±Ù
    [¿¾ ¿ë¾î] ÃÑ´ã°ü°ý¾à±Ù
  • Common tendinous ring
    ¿ÂÈûÁÙ°í¸®
    [¿¾ ¿ë¾î] ÃѰǷû
  • COMMON INTEGUMENT
    ¿ÜÇÇ
    [¿¾ ¿ë¾î] ¿ÜÇÇ
  • Common osseous crus
    ¿Â¹Ý°í¸®»À°ü´Ù¸®
    [¿¾ ¿ë¾î] °ñÃѰ¢
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • diaminopimelate pathway
    ÀÌ(ì£)¾Æ¹Ì³ëÇǸá»ê °æ·Î(ÌèÖØ)
  • direct oxidation pathway
    "Á÷Á¢»êÈ­°æ·Î(òÁïÈß«ûùÌèÖØ), (ÔÒ) hexose monophosphate shunt"
  • ED pathway
    ED °æ·Î(ÌèÖØ)
  • Embden-Meyerhof pathway
    ¿¥µ§-¸¶À̾îÈ£ÇÁ °æ·Î(ÌèÖØ)
  • Entner-Doudoroff pathway
    ¿£Æ®³Ê-µÎµµ·ÎÇÁ °æ·Î(ÌèÖØ)
  • extrinsic pathway
    ¿ÜÀÎ °æ·Î (èâì×ÌèÖØ)
  • feeder pathway
    °ø±Þ °æ·Î (ÍêÐåÌèÖØ)
  • fumarate pathway
    Ç»¸¶¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glucuronate pathway
    ±Û·çÅ¥·Ð»ê(ß«) °æ·Î(ÌèÖØ)
  • glucuronic acid oxidation pathway
    ±Û·çÅ¥·Ð»ê(ß«) »êÈ­°æ·Î(ß«ûùÌèÖØ)
  • glycerate pathway
    ±Û¸®¼¼¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glycolytic pathway
    ´çºÐÇØ °æ·Î(ÓØÝÂú°ÌèÖØ)
  • hexose diphosphate pathway
    ÀÌÀλê(ì£×òß«) Çí¼Ò½º °æ·Î (ÌèÖØ)
  • hexose monophosphate oxidative pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º »êÈ­°æ·Î (ß«ûùÌèÖØ)
  • hexose monophosphate pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º °æ·Î(ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CMR cardiomodulorespirography; cerebral metabolic rate; chief medical resident; common medical record; c...
HCPCS Health Care Financing Administration common procedural collecting system; Health Care Financing Admi...
DIC Disseminated(=Diffuse) Intravascular Coagulation syndrome; ÆÄÁ¾¼ºÇ÷°ü³»ÀÀ°í(÷ëðúàõúìηҮëêͳ) ÁõÈıº
  = ...
CCF cancer coagulation factor; cardiolipin complement fixation; carotid-cavernous fistula; centrifuged c...
coag coagulation, coagulated
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LACI Lipoprotein Associated Coagulation Inhibitor
MCT Microwave coagulation therapy
PMCT Percutaneous microwave coagulation therapy
DIC diffuse intravascular coagulation
AP accessory pathway
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • thermal coagulation
    ¿­ ÀÀ°í
  • common
    ÀϹÝÇü
  • common atrioventricular canal
    °øÅë ¹æ½Ç°ü
  • common bile duct
    ÃÑ ´ã°ü
  • common carotid artery
    ÃÑ ¸ñµ¿¸Æ, ÃÑ °æµ¿¸Æ
    µÎ°æºÎ¿¡ ºÐÆ÷ÇÏ´Â µ¿¸ÆÀÇ ÁÖµÈ °¡Áö·Î ¿ì´Â ¿ÏµÎµ¿¸Æ¿¡¼­ Á´ ´ëµ¿¸Æ±Ã¿¡¼­ °¢°¢ ºÐ±âÇÏ¿© ±â°ü°ú ÈĵÎÀÇ ¿ÜÃøÀ» Áö³ª¼­ »óÇàÇÏ¿© °©»ó ¿¬°ñ »ó¿¬ÀÇ ³ôÀÌ¿¡¼­ ³»°æµ¿¸Æ°ú ³»°æµ¿¸ÆÀ¸·Î ³ª´µ¾îÁø´Ù.
  • common carotid plexus
    ¿Â¸ñ µ¿¸Æ ½Å°æ ¾ó±â, ÃÑ °æµ¿¸Æ ½Å°æÃÑ
  • common drug
    º¸Åë ¾à
  • common facial vein
    ¿Â ¾ó±¼ Á¤¸Æ, ÃѾȸé Á¤¸Æ
  • common feature
    ÀϹÝÀûÀÎ ¼Ò°ß
  • common iliac artery
    ÃÑÀå°ñ µ¿¸Æ
  • common interosseous artery
    ÃÑ»À »çÀÌ µ¿¸Æ, ÃѰñ°£ µ¿¸Æ
  • common migraine
    ÀÏ¹Ý ÆíµÎÅë, ÀϹÝÀûÀÎ ÆíµÎÅë, ÀϹÝÀû ÆíµÎÅë, ÀϹÝÇü ÆíµÎÅë
    migraine without aura¸¦ º¸½Ã¿À.
  • common mole
    ½É»ó ¸ð¹Ý
  • common nasal meatus
    ÃÑ ºñµµ
  • common palmar digital artery
    ¿Â ¹Ù´ÚÂÊ ¼Õ°¡¶ô µ¿¸Æ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
light coagulation The coagulation of tissue by an intense beam of light, including laser (laser coagulation). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, haemorrhages, and malignant and benign neoplasms.
(12 Dec 1998)
lipoprotein-associated coagulation inhibitor Formerly known as anticonvertin; a protein that inhibits the extrinsic pathway of coagulation by binding to the tissue factor III-factor VII-Calcium-factor Xa complex.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
alternative oxidase pathway Pathway of mitochondrial electron transport in higher plants, particularly in fruits and seeds, that does not involve cytochrome oxidase and thus is resistant to cyanide.
(18 Nov 1997)
alternative pathway See: complement activation.
(18 Nov 1997)
anabolic pathway <biochemistry> A reaction or series of reactions in a metabolic pathway that synthesise complex molecules from simpler ones, usually requiring the input of energy.
Compare: catabolic pathway.
(09 Oct 1997)
auditory pathway Neural paths and connections within the central nervous system, beginning at the organ of Corti's hair cells, continuing along the eighth nerve, and terminating at the auditory cortex.
(05 Mar 2000)
GABA pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
Palade pathway <cell biology> The routing of proteins from the site of their synthesis to the final cellular or secreted position. Several different pathways are known and others suspected. Glycosylation of the proteins may provide specific address labels for the proteins.
(18 Nov 1997)
catabolic pathway <biochemistry> A series of reactions in a metabolic pathway that break down complex compounds into simpler ones, usually releasing energy in the process.
Compare: anabolic pathway.
(16 Mar 1998)
pathway 1. A collection of axons establishing a conduction route for nerve impulses from one group of nerve cells to another group or to an effector organ composed of muscle or gland cells.
2. Any sequence of chemical reactions leading from one compound to another; if taking place in living tissue, usually referred to as a biochemical pathway.
(05 Mar 2000)
visual pathway Neural paths and connections within the central nervous system, beginning with the retina and terminating in the occipital cortex.
(05 Mar 2000)
pentose phosphate pathway <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
perforant pathway A pathway of fibres originating in the lateral part of the entorhinal area, perforating the subiculum of the hippocampus, and running into the stratum moleculare of the hippocampus, where these fibres synapse with others that go to the dentate gyrus. It is also called the perforating fasciculus.
(12 Dec 1998)
mercapturic acid pathway A glutathione-dependent pathway for the detoxification of a number of compounds, including arene oxides; an S-substituted glutathione is formed and ultimately converted to a mercapturic acid (an S-substituted N-acetylated l-cysteine), which is excreted; the leukotrienes are believed to be degraded through this pathway.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • common factor
    =COMMON DIVISOR
  • common fraction
    »óºÐ¼ö
  • common gas
    ·¹±Ö·¯(¹«¿¬) ÈÖ¹ßÀ¯
  • common gender
    Å뼺(³²³à ¾ç¼º¿¡ ÅëÇÏ´Â `parent'µî)
  • common good
    °øÀÍ
  • common ground
    (»çȸ °ü°è.³íÀï.»óÈ£ ÀÌÇØ µîÀÇ)°øÅë±â¹Ý;µ¿°¨ÀÌ¿ä!
  • common informer
    Á÷¾÷Àû ¹Ð°íÀÚ
  • common jury
    (ÀϹÝÀÎÀ¸·Î µÈ)º¸Åë ¹è½É
  • common land
    °øÀ¯Áö;°ø¿ëÁö
  • common law
    °ü½À¹ý;ºÒ¹®À²
  • common lodging (house)
    °£ÀÌ ¼÷¹Ú¼Ò
  • common logarithm
    »ó¿ë ´ë¼ö
  • common market
    °øµ¿½ÃÀå
  • common marketeer
    EEC°¡ÀÔ Âù¼ºÀÚ
  • common measure
    °ø¾à¼ö;=COMMON TIME;º¸Åë·ü µî)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á